- Home
- XXII vs ONCO Comparison
XXII vs ONCO Comparison
Compare XXII & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- ONCO
- Stock Information
- Founded
- XXII 1998
- ONCO 2018
- Country
- XXII United States
- ONCO United States
- Employees
- XXII N/A
- ONCO N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- ONCO Health Care
- Exchange
- XXII Nasdaq
- ONCO Nasdaq
- Market Cap
- XXII 2.0M
- ONCO 1.8M
- IPO Year
- XXII N/A
- ONCO 2022
- Fundamental
- Price
- XXII $1.65
- ONCO $2.83
- Analyst Decision
- XXII
- ONCO
- Analyst Count
- XXII 0
- ONCO 0
- Target Price
- XXII N/A
- ONCO N/A
- AVG Volume (30 Days)
- XXII 200.6K
- ONCO 106.7K
- Earning Date
- XXII 08-14-2025
- ONCO 08-14-2025
- Dividend Yield
- XXII N/A
- ONCO N/A
- EPS Growth
- XXII N/A
- ONCO N/A
- EPS
- XXII N/A
- ONCO N/A
- Revenue
- XXII $21,362,000.00
- ONCO $1,326,959.00
- Revenue This Year
- XXII $22.41
- ONCO N/A
- Revenue Next Year
- XXII $76.35
- ONCO N/A
- P/E Ratio
- XXII N/A
- ONCO N/A
- Revenue Growth
- XXII N/A
- ONCO N/A
- 52 Week Low
- XXII $1.72
- ONCO $2.61
- 52 Week High
- XXII $1,571.13
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- XXII 20.98
- ONCO 43.21
- Support Level
- XXII $1.72
- ONCO $2.82
- Resistance Level
- XXII $2.45
- ONCO $3.20
- Average True Range (ATR)
- XXII 0.11
- ONCO 0.19
- MACD
- XXII 0.16
- ONCO 0.06
- Stochastic Oscillator
- XXII 0.00
- ONCO 56.90
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.